Valuation Metrics Reflect Improved Price Attractiveness
As of 22 April 2026, Krsnaa Diagnostics trades at ₹612.85, down 1.87% from the previous close of ₹624.55. The stock’s 52-week range spans ₹581.00 to ₹891.80, indicating a significant correction from its highs. This price movement has contributed to a recalibration of valuation metrics, with the P/E ratio settling at 24.73 and the P/BV ratio at 2.15. These figures have prompted MarketsMOJO to upgrade the company’s valuation grade from attractive to very attractive, a rare positive shift amid a challenging market backdrop.
Comparatively, peers in the healthcare diagnostics space remain priced at elevated multiples. For instance, Aster DM Healthcare and Krishna Institute command P/E ratios of 94.78 and 93.19 respectively, while Dr Lal Pathlabs trades at a P/E of 43.99. Even the more affordable Health.Global sports a P/E of 269.85, underscoring the relative bargain Krsnaa Diagnostics currently offers.
Enterprise Value Multiples and Profitability Ratios
Beyond P/E and P/BV, enterprise value (EV) multiples further highlight Krsnaa’s valuation appeal. The EV to EBITDA ratio stands at 10.21, markedly lower than peers such as Vijaya Diagnostics (34.84) and Metropolis Healthcare (28.55). This suggests that the market is pricing Krsnaa’s operating earnings at a discount relative to its competitors, potentially reflecting concerns over growth or operational risks but also signalling upside if these risks abate.
Profitability metrics remain modest but stable. The company’s return on capital employed (ROCE) is 11.01%, while return on equity (ROE) is 9.16%. These figures, while not industry-leading, indicate a reasonable efficiency in capital utilisation and shareholder returns, supporting the valuation upgrade.
Stock Performance Versus Sensex and Sector Trends
Krsnaa Diagnostics’ recent stock performance has lagged broader market indices. Year-to-date, the stock has declined by 14.92%, compared to a 6.98% fall in the Sensex. Over the past year, the divergence is starker, with Krsnaa down 24.07% while the Sensex remained nearly flat (-0.17%). However, over a three-year horizon, the stock has delivered a 14.74% return, albeit trailing the Sensex’s 32.89% gain. This relative underperformance may have contributed to the valuation reset, creating a more attractive entry point for value-oriented investors.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
Peer Comparison Highlights Valuation Disparities
When benchmarked against its healthcare diagnostics peers, Krsnaa Diagnostics stands out for its comparatively modest valuation multiples. The company’s EV to EBIT ratio of 17.84 and EV to capital employed of 1.99 are significantly lower than those of larger rivals, indicating a market perception of lower growth or higher risk but also a potential margin of safety for investors.
Notably, the PEG ratio of 4.29, while elevated, is still below some peers such as Rainbow Children (6.13) and Jeena Sikho (6.78), suggesting that the market’s expectations for earnings growth relative to price are somewhat more tempered but not out of line with sector norms.
Quality Grades and Market Sentiment
MarketsMOJO’s Mojo Score for Krsnaa Diagnostics currently stands at 38.0, with a Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 6 February 2026. This upgrade reflects a cautious optimism driven by improved valuation metrics, though the overall sentiment remains negative due to ongoing operational challenges and competitive pressures within the healthcare services sector.
The company’s small-cap market capitalisation further adds to the risk profile, as liquidity constraints and volatility tend to be higher in this segment. Investors should weigh these factors carefully against the improved valuation backdrop.
Holding Krsnaa Diagnostics Ltd from Healthcare Services? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Outlook and Investor Considerations
While Krsnaa Diagnostics’ valuation parameters have improved markedly, investors should remain mindful of the broader sector dynamics and company-specific risks. The healthcare diagnostics industry is characterised by intense competition, regulatory scrutiny, and evolving technology demands. Krsnaa’s moderate ROCE and ROE suggest room for operational improvement, which could further enhance valuation if realised.
Moreover, the stock’s recent underperformance relative to the Sensex and sector peers may reflect market concerns over growth sustainability and margin pressures. However, the current very attractive valuation grade provides a potential entry point for investors with a medium to long-term horizon who are willing to tolerate volatility in exchange for value.
In summary, Krsnaa Diagnostics Ltd’s shift in valuation from attractive to very attractive, supported by reasonable P/E and P/BV ratios and favourable EV multiples, positions the stock as a noteworthy candidate for value-focused portfolios within the healthcare services sector. Continuous monitoring of operational performance and sector trends will be essential to assess the sustainability of this valuation advantage.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
